Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative zanidatamab with chemotherapy for HER2-positive operable gastroesophageal adenocarcinoma
2025-523483-20-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanidatamab and tislelizumab in gastroesophageal junction adenocarcinoma (2 arms), sponsored by UZ Leuven. Primary endpoints: Safety during neoadjuvant period and Pathologic complete response. Planned start Aug 2026; status: authorised.
02
Drugs
zanidatamabtislelizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-523483-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523483-20-00.